iLite® CD3 Effector
BM5005
The iLite® CD3 Effector cell is optimized for quantifying T cell-mediated cytotoxicity and bispecific antibody function via CD3 engagement.
- High sensitivity and large dynamic range
- "Assay-ready" format for rapid and convenient use
- Reproducible and biologically relevant results
- Reduced assay variability and higher reproducibility compared to cells in culture
- Normalization of cell counts and serum matrix effects using a second reporter gene
Product Overview
The iLite® CD3 Effector Assay Ready Cells are human-engineered cells (Jurkat, ATCC #TIB-152) to be used for the assessment of CD3-mediated T-cell activation.
The CD3 Effector Assay Ready cells can be used alone or in combination with a target cell to measure a biological response when the NFAT pathway is induced by activation of the CD3 receptor on the effector cell, resulting in the reporter luciferase expression.
FOR RESEARCH USE ONLY
How it works
Principle of iLite® T-cell activation bioassays
Our two-cell T-cell activation bioassays consist of target cells expressing the antigen under study and effector cells expressing CD3/TCR Complex. Target control cells that do not express the antigen are also available. The effector cells contain two luciferase genes: an inducible Firefly luciferase gene and a constitutively expressed Renilla luciferase gene used for control purposes.
What's in the box?
>250 µL of iLite® Assay Ready Cells suspended in cryoprotective medium.
Specifications
| Product code | BM5005 |
| Assay target | CD3 |
| Technology | Cell-based reporter gene assay |
| Detection system | Luminescence |
| Regulatory status | Research Use Only |
| Assay time | 5h |
Documents
Downloads
Quantification of Bispecific Antibody Mediated T-cell Activation
Read post.jpg?width=500)
Bispecific Antibodies – Quantifying Their Activity Using iLite® Bioassays
Read post
Navigating the Complexities of Cell-based Assays in GMP QC Testing: The Journey to Robust Assays
Read post
Cell-based Assays in Immuno-oncology: Advancing Bispecific Antibody Development
Read post
The Value of Assay-Ready Cells in Providing Biologically Relevant Data for Robust Therapeutic Develo...
Read post
How Biosimilars Are Expanding Options for Patient Care
Read post
Biosimilar Development: Experts Discuss Analytical Characterization Toolkits for Antibody Therapeuti...
Read post
The Future of Drug Development for Complex Pathologies: Versatile Cell-based Assays and Customizable...
Read post
Webinar - Advancements in GMP QC Testing: A Comprehensive Guide to Cell-Based Assays
Read post
